TRANSLATIONAL RELEVANCE: Utilization of patient-derived xenograft (PDX) models in preclinical breast cancer research has been recognized as a more realistic solution to accurately recapitulate the features of patient tumors. In this study, we established two PDX models from two individual hormone receptor-positive (HR+)/HER2+ tumors for preclinical drug examination.
INTRODUCTION
Hormone receptor-positive (HR+)/HER2+ tumors account for approximately 10% of all breast cancers. Activation of estrogen receptor alpha (ERα) promotes the growth of HR+ tumors.
HR+/HER2-patients are treated with endocrine therapies, such as aromatase inhibitors (AIs) and ERα antagonists (1) (2) (3) . HER2 belongs to receptor tyrosine kinase (RTK) family. In the clinical setting, trastuzumab is the current standard treatment for HR-/HER2+ patients. A combination of HER2-targeting agents and chemotherapies is recommended for HER2+ advanced breast cancer (4) . HR+/HER2+ breast cancer is heterogeneous and bears the concurrent activity of ER and HER2 (3) (4) (5) (6) . The HR+ status implies that ER pathway plays a critical role in directing the clinical features of HR+/HER2+ breast cancer. While chemotherapy is typically applied, the increased HR level in HR+/HER2+ tumors is correlated to a better response to endocrine therapies (4) (5) (6) . Therefore, the use of chemotherapy may over-treat this subgroup of breast cancer patients, causing potentially unnecessary adverse events and economic cost (6) . Additionally, tumor response to trastuzumab may be reduced by concurrent activity of the ER pathway (7). Clinical studies show that the addition of anti-HER2 therapies significantly improves the clinical outcomes of HR+/HER2+ patients treated with AIs (8).
Clinical and laboratory studies also suggest that cross-talk between the ER and RTK signaling pathways plays a critical role in resistance to endocrine therapies and anti-HER2 agents in HR+/HER2+ breast cancers (3, 5) . The molecular mechanisms of acquired and de novo resistance to anti-HER2 agents vary in different biological contexts. Several studies reveal that Author Manuscript Published OnlineFirst on October 27, 2017; DOI: 10.1158/1078-0432.CCR- 17-1983 7 ERα signaling is augmented in the presence of anti-HER2 agents (9, 10). Notably, cancer cell lines resistant to anti-HER2 agents are often sensitive to the pure anti-estrogen-fulvestrant. In addition, activation of the PI3K/AKT/mTOR signaling has been reported in the establishment of endocrine resistance, leading to estrogen-independent ERα activation. In clinic, the mTORC1 inhibitor everolimus has been prescribed with endocrine agents for advanced and AI-resistant HR+ breast cancers (11-16).
The PI3K/AKT/mTOR axis, as the downstream of the RTK cascade, is considered to be a promising therapeutic target in HR+ and HER2+ breast cancers (14) (15) (16) . The protein kinase mTOR, which exists in two complexes-mTORC1 and mTORC2 and serves as the catalytic subunit, transduces proliferation cues to the signaling components of the PI3K/AKT/mTOR axis.
While activation, PI3K and mTORC2 activate AKT, leading to up-regulation of mTORC1 and the downstream S6K1 and 4EBP1 for promoting cell proliferation and survival (16) (17) (18) (19) (20) . Due to the PI3K/AKT rebound effect, long-term treatment of mTORC1 inhibition has been known to alleviate AKT activation by mTORC2. Therefore, allosteric mTOR inhibitors (e.g. everolimus) do not fully inhibit mTORC1 activity (19) . To overcome this barrier, the ATP-competitive dual mTOR kinase inhibitors, such as MLN0128, are developed to simultaneously target both mTORC1 and mTORC2 (20) .
Presently, there are a few HR+/HER2+ breast cancer cell lines available for preclinical research (9), which are limits in understanding the clinical features of patient tumors. Instead, PDXs mimicking the features from the tumors of origin can offer a realistic solution (21) . In this 
MATERIALS AND METHODS

Patient-derived xenografts and in vivo treatment study
Surgical resections (2×2 mm 2 ) from consented HR+/HER2+ breast cancer patients were orthotopically engrafted into the mammary fat pad of 6~8-week-old female NOD-scid/IL2Rγ
-/-(NSG) mice to derive parental tumors. To examine estrogen-dependent growth, tumor slices (2~3 mm) from the parental tumors and in-house-made estrogen pellets containing 1 mg of E2 each were simultaneously implanted into the mammary fat pad of 6-week-old ovariectomized NSG mice (22) . For in vivo drug efficacy examination, tumor slices (2~3 mm) from the parental tumors were engrafted into the intact NSG mice. Once tumors were established to be 100~200 mm 3 in size, mice were randomized and then subjected to four-week treatment of control (150 µL sterile saline, twice weekly of intraperitoneal injection), trastuzumab (10 mg/kg in sterile saline, twice weekly of intraperitoneal injection), fulvestrant (5 mg in 100 µL sterile saline, once weekly/subcutaneous injection) and/or MLN0128 (0.3 mg/kg in 5% N-methyl-2-pyrrolidone, 15%
polyvinyl pyrrolidone in water, six days weekly of gavage) (15) . Tumor growth and body weight were monitored twice per week and tumor volume was calculated as length × width 2 × π/6 (23).
Fulvestrant (Faslodex, AstraZeneca, London, England) and trastuzumab (Genentech, San
Francisco, CA, USA) were obtained from the City of Hope National Medical Center Pharmacy. Association for Assessment and Accreditation of Laboratory Animal Care and operated according to NIH guidelines.
Histological analysis
Immunohistochemistry (IHC) and H&E (hematoxylin and eosin) staining of formalin-fixed tumor tissues were performed by the Pathology Core facility at City of Hope. Antibodies used in IHC included ERα (ab1660; Abcam, Cambridge MA), PR (PA0312; Leica Biosystems Inc., Buffalo Grove IL), HER2 (A0485; DAKO/Agilent Technologies, Santa Clara CA), and Ki-67 (M7240; DAKO). Hormone receptors were interpreted and scored according to joint American Society of Clinical Oncology/College of American Pathologists guidelines (24, 25) . Slides were reviewed first at 10X magnification to identify areas of positive staining, followed by confirmation and quantitation at 20~40X magnifications. Ki-67 was scored by identifying areas of most abundant positivity at low magnification, followed by manual counting of 10 high-power (40X) fields.
Representative images and scoring were acquired using an Olympus BX46 microscope with DP27 camera and Olympus CellSens software (Olympus, Shinjuku, Japan).
RNA sequencing and data analysis
Total RNA from six and three COH-SC1 and COH-SC31 PDX tumors, respectively, and two biological replicates from an ER+/HER2-PDX established in our laboratory (indicated as REF in Figure 3A) were extracted using RNeasy Extract Kit (Qiagen, Alameda, CA) and then subjected and Gene Set Enrichment Analysis (GSEA) were summarized in SUPPLEMENTARY MATERIALS AND METHODS. All sequencing data were submitted to GEO database.
Reverse phase protein array (RPPA) analysis
Three snap-frozen tumor samples from COH-SC1, COH-SC31, and an ER+/HER2-PDXs were subjected to RPPA analysis probed a total of 232 antibodies conducted by the MD Anderson Cancer Center Functional Proteomics RPPA Facility as described previously (26) . To define the relatively activated signaling in either COH-SC1 or COH-SC31 model, RPPA data of an ER+/HER2-PDX was used as the reference (indicated as REF in Figure 3C ).
Research. 
RESULTS
Establishment and characterization of two HR+/HER2+ breast PDX models
To decipher the biology and potential therapeutic strategy of HR+/HER2+ breast cancers, two PDXs named as COH-SC1 and COH-SC31 were established. As shown in Figure 1A , surgical resections from consented HR+/HER2+ breast cancer patients were engrafted into the mammary fat pad of immunodeficient NSG mice to derive parental tumors (Step 1). Once established, parental tumors were divided into pieces and subsequently implanted to 30~40 mice for the following molecular and pharmacologic analyses. Samples from individual clones were subjected to RNA-seq transcriptome and RRPA proteome analyses to dissect the molecular features of the two PDXs. "Same-patient-on-all-arms" testing cohorts were generated for drug efficacy examination (Step 2). Drug-mediated tumor growth and phenotypic/molecular changes were then investigated (Step 3).
COH-SC1 was derived from an ER+/PR-/HER2+ breast tumor prior to treatment and the patient later responded well to trastuzmab plus chemotherapies; COH-SC31 was established from a trastuzumab-resistant ER+/PR+/HER2+ metastatic breast tumor (Supplementary Table 1 ).
H&E staining indicated that cell morphologies between PDXs and the corresponding patients' samples are similar in both models, which COH-SC1 tumors are moderately differentiated but poor-differentiation in COH-SC31 (Supplementary Figure 1A) . IHC analyses of ER, PR, and 
Distinct trastuzumab response in COH-SC1 and COH-SC31 PDXs
Trastuzumab is the first-line monotherapy of HER2+ breast cancer (4-7). To validate its 
Characterization of molecular features and clinical relevance of two PDXs
To decode molecular features of HR+/HER2+ breast cancers and explore potential therapeutic shown in the box areas were subjected to IPA to uncover that RTK (i.e. EGFR, HER2, and HER3) and PI3K/AKT/mTOR pathways are the mostly significant networks in the two studied models Author Manuscript Published OnlineFirst on October 27, 2017; DOI: 10.1158/1078-0432.CCR- (Supplementary Figures 4B, 5A, and 5B). For example, expression levels of ESR1 (10.64 fold) and well-known ERα-targeted loci, such as TFF1 (657.11 fold) and BMP7 (203.42 fold), were higher in COH-SC31 in relation to that of COH-SC1 (Supplementary Table 2 ). Summarization of these findings proposed that PI3K/AKT/mTOR signaling is a critical oncogenic pathway in both PDXs but ERα signaling plays a more dominated role in COH-SC31 model. To corroborate this concept, we examined the drug efficacy in vivo on both COH-SC1 and COH-SC31 PDXs. In trastuzumab-sensitive COH-SC1 model, TRA-plus-MLN combination significantly suppressed ~80.5% tumor growth (see "Comb" in Supplementary Figure 6A) . But, it concurrently increased ER-expressing cell population (see "Comb" in Supplementary Figure   6D ), implying that simultaneous blockade of ERα and mTOR pathway is another therapeutic scheme against trastuzumab-sensitive HR+/HER2+ cancer, which can potentially lower the recurrence risk resulting from the increasing ER expression. Since activated PI3K/AKT/mTOR and ERα pathways were found to be involved in tumor progression of HR+/HER2+ cancers via integrative omics analysis (Figures 3 and Supplementary Figures 4 and 5) , we, thus, tested the efficacy of combined MLN with anti-estrogen fulvestrant (FUL) on the two preclinical cohorts Author Manuscript Published OnlineFirst on October 27, 2017; DOI: 10.1158/1078-0432.CCR- larger extent than that in COH-SC1 ( Figure 1B) . The transcriptome analysis additionally pointed to the relative elevation of ER signaling and it function readouts, such as SERPINA1 (34), in COH-SC31 model compared to that of COH-SC1 (Supplementary Figures 1C & 4B) .
Moreover, the expression patterns of SERPINA1, SIAH2 and EZH2 identified from the transcriptome profiling reflected the pharmacological behaviors of COH-SC1 and COH-SC31 to fulvestrant treatment. It has been documented that high levels of SERPINA1 predict good response to endocrine therapy as similar as our previous observation (34); low expression of SIAH2 is associated with resistance to endocrine therapies in vitro and in clinic (35, 36) ; reduction of EZH2 expression re-sensitizes cancer cells to anti-estrogens (37) . In vivo drug efficacy examination supportively confirmed that COH-SC31 is more responsive to fulvestrant in relation to COH-SC1 does (see "FUL" in Figure 5A ). As a result, endocrine therapies should be included to treat HR+/HER2+ breast cancers expressing high levels of ERα or activated estrogen-dependent ERα signaling, especially for those developed trastuzumab resistance.
The bidirectional interaction between ER and RTK pathways frequently conferred resistance to single-drug treatment of endocrine therapy or HER2-targeted therapy. PI3K/AKT/mTOR signaling contained multiple components (e.g. AKT) involved in these processes (3-5, 9). (13, 38, 39) . But, overall survival (OS) was not benefited from the addition of mTORC1 inhibitors, which may be due to the PI3K/AKT rebound effect, resulting in the alleviation of AKT (40) . Instead, MLN0128 targeting to both mTORC1 and mTORC2 was developed to treat HR+ as well as HER2+ breast cancers in vitro and in vivo (15, 20, 41) . In ER+ breast cancer, dual mTORC inhibitors (e.g. AZD8055 and AZD2014) combined with endocrine agents exhibited superior inhibition effects on in vitro culture system or cell-based xenografts compared to that of single-drug treatment (14, 16) . Additionally, MLN combined with and the dual tyrosine kinase inhibitor-lapatinib has synergistic effects on HER2+ cancer cell lines and PDXs, which are resistant to anti-HER2 drugs (15) . At the present time, fulvestrant with either MLN or AZD2014 are being investigated in HR+/HER2-advanced metastatic breast cancer in phase II clinical trials.
To sum up, combination strategy with utilization of MLN may shed a light to treat HR+/HER2+ cancers.
In this study, we first observed that COH-SC1 PDX is more responsive to the first-line TRA treatment compared to COH-SC31 model (Figure 2A and Supplementary Figures 4 & 5) . In trastuzumab-sensitive and lower ER expressed COH-SC1 PDX (Figure 2A and Supplementary Figure 1C) , we conducted a dual-therapy treatment scheme using TRA and MLN to prove that combination therapy is more potent against tumor growth in relation to TRA or MLN monotherapy does (Supplementary Figure 6A) . In HR+/HER2+ breast cancers, ER signaling pathway is frequently activated while suppressing HER2 signaling (9, 10, 42), which potentially leads to resistance to anti-HER2 drugs and re-sensitization to endocrine therapies; this scenario was similar to that observed in COH-SC1 and COH-SC31 models ( Figure 5A and Supplementary Figure 6D 
27 medicine in effective breast cancer therapy (43) . However, cancer cell line models are limited in adequately reflecting tumor heterogeneity and morphology in vivo, which depreciates the predictive value of these models in drug discovery (21) . Alternatively, we utilize PDX technology to explore therapeutic strategies for individual HR+/HER2+ breast cancer. what we experienced in this study. Also, while it is difficult to expand the PDX lines in a timely manner, the study has to be carefully prioritized.
In summary, we have generated two HR+/HER2+ breast PDX models that exhibit different molecular and pharmacological features, compared to the currently available cell line models. 
28
The establishment and characterization of these two PDX models broadens the representation of HR+/HER2+ breast cancer research tools with more diverse genetic profiles and clinical relevance. We have provided new preclinical models to clinicians and scientists in tailoring therapeutic strategies for this 10% of the total breast cancer population, by demonstrating that 1) dual mTORC inhibitor MLN sensitizes HR+/HER2+ breast cancers to TRA or FUL treatment; 2) the level of estrogen-mediated ER activity in affecting pharmacological behaviors in HR+/HER2+ breast cancers; 3) tumors with higher ER activity in tending to be more responsive to FUL. cancer patients within expression of the boxed genes identified in COH-SC1 (A) or COH-SC31
(B) models, respectively. Log-rank test was used to determine statistical significance. 
